Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022
Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
The transaction is anticipated to close in the first quarter of 2022
The first clinical trial is expected to commence in early 2022 both in Europe and the US
More than 90,000 patients utilise the services daily
The state-of-the-art facility provides a pathway from development to large-scale biologics production
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
This project will be conducted at the “NURA,” a health screening centre that Fujifilm opened in India in February this year
Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
Subscribe To Our Newsletter & Stay Updated
